DAC NOFO amendment 0004 to announce Phase I results signed.pdf

Amendment 0004 for the NOFO # 95332418N0003

NOFO Name: “Data Analytics Center Project in Côte d’Ivoire”

Subject: Phase I results, Expression of Interests and the Phase II teleconference

With this Amendment 0004, the Millennium Challenge Corporation (MCC) is pleased to announce applicants

(“consortium coordinating partners”) that are invited to participate in Phase II of the above-referenced Notice of

Funding Opportunity (NOFO) based on Section H of the NOFO – and provide all applicants with guidance on next steps. In this amendment, we are also providing a list of EOIs submitted so far.

I. Successful Phase I applicants that are invited to participate in Phase II are:

1. Global Challenge Corporation

Lot 2027/Ilot 116/ Rue I 146

Riviera- Palmeraie, Abidjan 23 BP 2612 Abidjan, Côte d’Ivoire

Partners:

Council of Organizations for Fight against AIDS and other Pandemic Diseases in Côte d'Ivoire (COSCI). Cocody les deux Plateaux, Rue K 32. 01 BP 12125 Abidjan, Côte d’Ivoire

SBC4D. 5 rue de la Champagne. 31100 Toulouse, France

Development Gateway, Inc. 1110 Vermont Avenue. NW Suite 500. Washington, DC 20005

USA

2. SEJEN CI

ABIDJAN, ABOBO SOGEFIHA

FuturAfric, Cocody Abidjan, Cote d’Ivoire

Superior Consulting, 350 West Burnsville Pkwy, Ste. 550, Burnsville, MN, ENSEA, Rue des Peintres, Abidjan, Cote d’Ivoire

Agence Emploi Jeunes, Plateau, Blvd Clozel, Immeuble Perignon

II. Phase II applicants that applied but are NOT selected to continue to Phase II are:

1. CREFDI (Centre de Recherche Et de Formation sur le Développement Intégré).

Region of Abidjan, City of Bingerville, crossroads CIE lot 633

25 B.P. 1496 Abidjan 25

2. CyberTechs, Abidjan, Cocody, 24BP 147

Abidjan 24, Cote d’Ivoire

Jigsaw Academy, India

The MathCompany, India

Organizations that were part of teams not selected to participate in Phase I are eligible to partner with those organizations that are continuing on to Phase II, if their participation helps to strengthen a particular team’s technical capabilities and qualifications as laid out in the NOFO and needed to reach intended DAC project outcomes.

III. The list of Expression of Interests (EOI) submitted so far include:

Finally, below are the list of organizations that have expressed an interest in the DAC and could also be involve as partners by applicants continuing on to Phase II.

1. Organization Name: HaiGiS Contact: Simon Dedjo Yao, Chief Executive Officer | simondedjo@h-aigis.com

Tel: +225 476 902 73 | website: www.h-aigis.com

2. Organization Name: Medical Decision Logic, Inc. (“mdlogix” - www.mdlogix.com)

Whose team includes:

Allen Tien, MD, MHS, President and Director of Applied Research, allen@mdlogix.com

Aaditya Goswami, CEO, goswami@mdlogix.com

Matt Briner, Director of Clinical Products, mbriner@mdlogix.com

Stuart Sutley, Director of Strategy, ssutley@mdlogix.com

Jim Daly, Director of Marketing, jdaley@mdlogix.com

Eric Jones, PhD, Director of Network Science, ejones@mdlogix.com

3. Organization Name: Reboot Contact: Laura Freschi, Director of Partnerships | laura@reboot.org | Office: +1 212 388 1010

4. Organization Name: RippleNami, Inc.

Contact: Jaye Connolly-LaBelle, CEO, 2027 Newcastle Ave, #1161, Cardiff, California 92007

Contact Information: jaye@ripplenami.com www.ripplenami.com USA +1 (760) 822 3456

Consortia may continue forming during the Phase II pre-application submission. The partnerships between the consortia coordinating partners and sub-partners are not required to be exclusive – and organizations wishing to partner with groups continuing to Phase II are NOT required to submit an EOI.

IV. Phase II Teleconference (Phase II selected applicants only)

The Phase II Pre-Application Teleconference will be conducted via both Adobe Connect and a phone line.

Specifics for this teleconference will be sent directly to teams selected for Phase II. The overall purpose of the call will be to go over the information provided in the NOFO – and provide guidance to continuing teams.

Taylor Wolf, Agreement Officer

End of Amendment 0004 mailto:simondedjo@h-aigis.com http://www.mdlogix.com/ mailto:ejones@mdlogix.com